Limited guidance exists for the management of methamphetamine-associated PAH (Meth-APAH) and the experiences of physicians treating this population are not well documented. This study explored how physicians approach diagnosis and treatment and identified unmet needs in clinical care through structured interviews with 30 U.S. pulmonologists and cardiologists who manage patients with Meth-APAH.

Pulmonary endarterectomy (PEA) is a potentially curative treatment for chronic thromboembolic pulmonary hypertension (CTEPH); however, decompensated right heart failure and concomitant cardiac procedures increase the risk of postoperative mortality.

Use of subcutaneous treprostinil (TRE) in children with pulmonary hypertension (PH) secondary to lung disease (group 3 PH) is not well described. We hypothesized that initiation of TRE is associated with improvement in PH severity and right ventricular (RV) function with minimal early side effects. 

Pulmonary hypertension (PH) is a progressive and life-threatening disease characterized by pulmonary vascular remodeling that leads to elevated pulmonary artery pressures, and subsequent right ventricular dysfunction. 

In this PH Community Call, we discussed: 

• C–C Motif chemokine receptor-2 blockade ameliorates PH in rats and synergizes with a pulmonary vasodilator
• Deep-learning networks accurately detect pulmonary hypertension in patients with idiopathic pulmonary fibrosis
• Assessing the feasibility of using smartphone data to identify risk of idiopathic pulmonary arterial hypertension

Gouteng Jiangya Jieyu Prescription (GTJYJYP) shows potential in regulating blood pressure and improving mood. This study aims to investigate GTJYJYP's neuroprotective effects against neuronal damage and its underlying mechanisms in rats with hypertension complicated by depression (HD).

The first, Women's Health Task Force, webinar of 2026, exploring how biological sex influences pulmonary arterial hypertension (PAH) and respiratory disease.

I read with interest the study by Cassady and colleagues comparing healthcare utilization among patients with pulmonary hypertension associated with interstitial lung disease (PH-ILD) who initiated inhaled treprostinil versus matched patients who remained untreated in a large US administrative claims dataset. 

Eisenmenger syndrome (ES) represents an advanced stage of pulmonary arterial hypertension (PAH) associated with congenital heart disease. It is characterized by elevated pulmonary vascular resistance, with a right-to-left shunt and resting hypoxemia. ES is associated with high morbidity and mortality. 

Portopulmonary hypertension (PoPH) is a subtype of pulmonary arterial hypertension (PAH) associated with portal hypertension, occurring in 2%–6% of cirrhotic patients. Although guidelines recommend routine echocardiography before transplantation, the prevalence, and outcomes of PAH-specific therapy in cirrhotic patients remain unclear.